Geremia B. Bolli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Geremia B. Bolli has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
- Carmine Giuseppe Fanelli
Department of Medicine and Surgery Perugia University Medical School Perugia Italy
19 shared publications Paola Lucidi
Centro Diabetologia Asl 2 Umbria ‘Centro Storico’ Foligno Italy
19 shared publicationsFrancesca Porcellati
Department of Medicine and Surgery Perugia University Medical School Perugia Italy
16 shared publications- David R. Owens
Diabetes Research Group Swansea University Wales UK
11 shared publications Carmine G. Fanelli
Section of Endocrinology and Metabolism, Department of Medicine and Surgery, Perugia University School of Medicine, Perugia, Italy
8 shared publications- Matthew C. Riddle
Division of Endocrinology, Diabetes & Clinical Nutrition, Department of Medicine, Oregon Health & Science University, Portland, OR
8 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
The Ahlqvist Subphenotypes of Type 2 Diabetes: A Narrative Review of Scientific Evidence and Its Potential Contribution to Precision Diabetes
Background: Among several approaches, k‐means clustering has established as a widely used method to classify people with type 2 diabetes (T2D) into distinct subphenotypes, and the Ahlqvist T2D subphenotypes of Severe Insulin Deficient Diabetes (SIDD), Mild Age‐Related Diabetes (MARD), Mild Obesity Diabetes (MOD) and Severe Insulin Resistant Diabetes (SIRD) became the most replicated ones in diabetes cohorts since its introduction in 2018. This review summarises the current evidence gained from the Ahlqvist subphenotypes focusing on distribution patterns, key characteristics, comorbidities and their clinical implementation. Methods: We conducted a narrative literature search of PubMed for English‐language articles published from inception to June 2026 using combinations of the terms ‘k‐means clustering’, ‘classification of diabetes’, ‘ Ahlqvist methodology’, ‘type 2 diabetes’, ‘diabetes subphenotypes’ and ‘diabetes subtypes’. Literature was eligible which reported the same Ahlqvist classification method as originally applied. Results: Twenty‐eight cohorts were identified incorporating more than 97 000 people with diabetes. Ahlqvist subphenotypes have been studied mainly in White/European and East/South Asian populations but seldom in Black/Africans and Hispanic/Latin Americans. MARD and MOD had the highest prevalences among populations; SIDD had severe insulin deficiency and hyperglycaemia, and low fasting C‐peptide (FCP) levels; SIRD was insulin resistant with high FCP levels and incidence risk of nephropathy. Retrospective analyses of glycaemic responses to glucose‐lowering treatments did not clearly favour any drug regimen for subphenotypes. Conclusions: Ahlqvist T2D subphenotypes reflect the heterogeneity of T2D. However, clinical implementation is associated with many barriers, and further studies must prove the value of subphenotype‐guided management of T2D towards precision diabetes.
- 5 October 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
Open AccessThe Ahlqvist Subphenotypes of Type 2 Diabetes: A Narrative Review of Scientific Evidence and Its Potential Contribution to Precision Diabetes
Background: Among several approaches, k‐means clustering has established as a widely used method to classify people with type 2 diabetes (T2D) into distinct subphenotypes, and the Ahlqvist T2D subphenotypes of Severe Insulin Deficient Diabetes (SIDD), Mild Age‐Related Diabetes (MARD), Mild Obesity Diabetes (MOD) and Severe Insulin Resistant Diabetes (SIRD) became the most replicated ones in diabetes cohorts since its introduction in 2018. This review summarises the current evidence gained from the Ahlqvist subphenotypes focusing on distribution patterns, key characteristics, comorbidities and their clinical implementation. Methods: We conducted a narrative literature search of PubMed for English‐language articles published from inception to June 2026 using combinations of the terms ‘k‐means clustering’, ‘classification of diabetes’, ‘ Ahlqvist methodology’, ‘type 2 diabetes’, ‘diabetes subphenotypes’ and ‘diabetes subtypes’. Literature was eligible which reported the same Ahlqvist classification method as originally applied. Results: Twenty‐eight cohorts were identified incorporating more than 97 000 people with diabetes. Ahlqvist subphenotypes have been studied mainly in White/European and East/South Asian populations but seldom in Black/Africans and Hispanic/Latin Americans. MARD and MOD had the highest prevalences among populations; SIDD had severe insulin deficiency and hyperglycaemia, and low fasting C‐peptide (FCP) levels; SIRD was insulin resistant with high FCP levels and incidence risk of nephropathy. Retrospective analyses of glycaemic responses to glucose‐lowering treatments did not clearly favour any drug regimen for subphenotypes. Conclusions: Ahlqvist T2D subphenotypes reflect the heterogeneity of T2D. However, clinical implementation is associated with many barriers, and further studies must prove the value of subphenotype‐guided management of T2D towards precision diabetes.
- Open Access
- 27 April 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (7) , 5527-5541
The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long‐Acting Insulin Analogues for Diabetes Mellitus
In the year 2000 the first once daily long‐acting bioengineered insulin analogue (LAIA), insulin glargine (‘glargine’), a true basal insulin (BI), became available for clinical use. This led to the decline in the 50‐year‐old era and prominence of the intermediate‐acting insulins, neutral protamine Hagedorn (NPH) and lente, requiring twice daily administration to control the basal metabolism of people with type 1 diabetes (T1DM) and type 2 diabetes (T2DM). This milestone bridged the gap between regimens involving unmodified human insulins of the previous century to those referred to as using ‘designer insulins’, with the introduction 4 years previously of the meal‐time analogue, insulin lispro. The rapid gain in popularity of glargine is explained by its clinical benefits (once‐daily dosing, titration to achieve improved pre‐breakfast plasma glucose, with a lower risk of nocturnal hypoglycaemia compared to NPH, and less frequent blood glucose monitoring). These benefits correlate with the pharmacokinetic/pharmacodynamic characteristics of insulin glargine being closer to physiological BI supply. In T2DM glargine changed the paradigm of insulin substitution by embedding the concept of ‘treating‐to‐target’, by starting BI ‘early’, with focus on near‐normal fasting plasma glucose prior to the introduction of prandial insulin, and more recently in combination with GLP‐1 receptor agonists. These practices/principles have continued with the introduction of additional innovative LAIAs for once‐daily or indeed weekly use. Today glargine remains in widespread worldwide use in people with T1DM and T2DM, is often the initial BI used, while it serves as a reference against which other LAIAs are tested in clinical trials.
- 27 April 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (7) , 5527-5541
Open AccessThe Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long‐Acting Insulin Analogues for Diabetes Mellitus
In the year 2000 the first once daily long‐acting bioengineered insulin analogue (LAIA), insulin glargine (‘glargine’), a true basal insulin (BI), became available for clinical use. This led to the decline in the 50‐year‐old era and prominence of the intermediate‐acting insulins, neutral protamine Hagedorn (NPH) and lente, requiring twice daily administration to control the basal metabolism of people with type 1 diabetes (T1DM) and type 2 diabetes (T2DM). This milestone bridged the gap between regimens involving unmodified human insulins of the previous century to those referred to as using ‘designer insulins’, with the introduction 4 years previously of the meal‐time analogue, insulin lispro. The rapid gain in popularity of glargine is explained by its clinical benefits (once‐daily dosing, titration to achieve improved pre‐breakfast plasma glucose, with a lower risk of nocturnal hypoglycaemia compared to NPH, and less frequent blood glucose monitoring). These benefits correlate with the pharmacokinetic/pharmacodynamic characteristics of insulin glargine being closer to physiological BI supply. In T2DM glargine changed the paradigm of insulin substitution by embedding the concept of ‘treating‐to‐target’, by starting BI ‘early’, with focus on near‐normal fasting plasma glucose prior to the introduction of prandial insulin, and more recently in combination with GLP‐1 receptor agonists. These practices/principles have continued with the introduction of additional innovative LAIAs for once‐daily or indeed weekly use. Today glargine remains in widespread worldwide use in people with T1DM and T2DM, is often the initial BI used, while it serves as a reference against which other LAIAs are tested in clinical trials.
- Open Access
- 3 November 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (1) , 574-583
Importance of targeting post‐prandial hyperglycaemia to achieve HbA1c goals in insulin glargine‐treated subphenotypes of type 2 diabetes
Aims: To explore outcome parameters related to achieving HbA1c goal (n = 2,435) were clustered into T2D subphenotypes, with ≥97% having either Severe Insulin‐Deficient Diabetes (SIDD) (9%–22%), Mild Age‐Related Diabetes (MARD) (8%–18%), or Mild Obesity Diabetes (MOD) (56%–78%) across trials. Subphenotypes were stratified by HbA1c goal achievement (HbA1c <7.0%/responders or ≥7.0%/non‐responders), and efficacy and safety parameters were analysed both at baseline and after 26 weeks. Glargine groups were pooled. Results: With all basal insulin regimens, the responders were fewest in SIDD (19%–33%), followed by MOD (33%–56%) and MARD (42%–62%). Mean FPG at 26 weeks was slightly lower in responders (103–128 mg/dL; 5.8–7.1 mmol/L) compared to non‐responders (124–143 mg/dL; 6.9–7.9 mmol/L) in each subphenotype, despite equivalent or higher mean glargine doses in non‐responders. Self‐monitored post‐prandial glucose (PPG) was consistently above the recommended target of 140 mg/dL (7.8 mmol/L) in non‐responders, even in those on intensified insulin treatment. Hypoglycaemia risk was similar or only slightly increased in responders compared to non‐responders across subphenotypes. Conclusions: With glargine‐based regimens, strict control of PPG is necessary to attain HbA1c <7.0% across all T2D subphenotypes. Therefore, to achieve optimal treatment goals, especially in the SIDD subphenotype, appropriate dose adjustments of both basal and preprandial insulin are required.
- 3 November 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (1) , 574-583
Open AccessImportance of targeting post‐prandial hyperglycaemia to achieve HbA1c goals in insulin glargine‐treated subphenotypes of type 2 diabetes
Aims: To explore outcome parameters related to achieving HbA1c goal (n = 2,435) were clustered into T2D subphenotypes, with ≥97% having either Severe Insulin‐Deficient Diabetes (SIDD) (9%–22%), Mild Age‐Related Diabetes (MARD) (8%–18%), or Mild Obesity Diabetes (MOD) (56%–78%) across trials. Subphenotypes were stratified by HbA1c goal achievement (HbA1c <7.0%/responders or ≥7.0%/non‐responders), and efficacy and safety parameters were analysed both at baseline and after 26 weeks. Glargine groups were pooled. Results: With all basal insulin regimens, the responders were fewest in SIDD (19%–33%), followed by MOD (33%–56%) and MARD (42%–62%). Mean FPG at 26 weeks was slightly lower in responders (103–128 mg/dL; 5.8–7.1 mmol/L) compared to non‐responders (124–143 mg/dL; 6.9–7.9 mmol/L) in each subphenotype, despite equivalent or higher mean glargine doses in non‐responders. Self‐monitored post‐prandial glucose (PPG) was consistently above the recommended target of 140 mg/dL (7.8 mmol/L) in non‐responders, even in those on intensified insulin treatment. Hypoglycaemia risk was similar or only slightly increased in responders compared to non‐responders across subphenotypes. Conclusions: With glargine‐based regimens, strict control of PPG is necessary to attain HbA1c <7.0% across all T2D subphenotypes. Therefore, to achieve optimal treatment goals, especially in the SIDD subphenotype, appropriate dose adjustments of both basal and preprandial insulin are required.
- Open Access
- 17 July 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (S7) , 14-25
An overview of randomized clinical trials of fixed‐ratio combinations of basal insulin plus GLP ‐ 1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes
Advancing therapy in T2DM with injectables, i.e., basal insulin (BI) and GLP‐1 receptor agonists (GLP‐1RAs) is recommended after the failure of oral glucose lowering agents (OGLAs), BI alone, or BI in combination with OGLAs, especially in persons with, or at high risk of atherosclerotic cardiovascular disease (ASCVD). BI and GLP‐1RAs can be administered separately or as fixed‐ratio combinations (FRCs) for daily use (degludec+liraglutide, IDegLira, glargine‐100 + lixisenatide iGlarLixi) or weekly use (icodec+semaglutide, IcoSema). The currently available FRCs IDegLira and iGlarLixi differ in their respective BI as well as GLP‐1RA components. Liraglutide predominantly stimulates glucose‐dependent endogenous insulin secretion in response to nutrient challenges. In contrast, the rapid‐acting lixisenatide primarily delays gastric emptying over a few hours post‐dosing with little or no impact on insulin secretion. IDegLira in DUAL studies and iGlarLixi in LixiLan studies appear to have equivalent lowering effects on HbA1c, although IDegLira achieves a greater reduction in body weight. The weekly FRC IcoSema is superior to weekly insulin icodec (COMBINE 1), to semaglutide (COMBINE 2), and non‐inferior to basal‐bolus insulin therapy (COMBINE 3). Comparison of IcoSema with glargine‐100 is ongoing (COMBINE 4). However, all FRCs are limited by the low GLP‐1RA dose relative to the insulin delivered. Whenever higher GLP‐1RA doses are required (i.e., in obese people), the option of separate dosing of BI and GLP‐1RA with independent titration of each component should be considered.
- 17 July 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (S7) , 14-25
Open AccessAn overview of randomized clinical trials of fixed‐ratio combinations of basal insulin plus GLP ‐ 1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes
Advancing therapy in T2DM with injectables, i.e., basal insulin (BI) and GLP‐1 receptor agonists (GLP‐1RAs) is recommended after the failure of oral glucose lowering agents (OGLAs), BI alone, or BI in combination with OGLAs, especially in persons with, or at high risk of atherosclerotic cardiovascular disease (ASCVD). BI and GLP‐1RAs can be administered separately or as fixed‐ratio combinations (FRCs) for daily use (degludec+liraglutide, IDegLira, glargine‐100 + lixisenatide iGlarLixi) or weekly use (icodec+semaglutide, IcoSema). The currently available FRCs IDegLira and iGlarLixi differ in their respective BI as well as GLP‐1RA components. Liraglutide predominantly stimulates glucose‐dependent endogenous insulin secretion in response to nutrient challenges. In contrast, the rapid‐acting lixisenatide primarily delays gastric emptying over a few hours post‐dosing with little or no impact on insulin secretion. IDegLira in DUAL studies and iGlarLixi in LixiLan studies appear to have equivalent lowering effects on HbA1c, although IDegLira achieves a greater reduction in body weight. The weekly FRC IcoSema is superior to weekly insulin icodec (COMBINE 1), to semaglutide (COMBINE 2), and non‐inferior to basal‐bolus insulin therapy (COMBINE 3). Comparison of IcoSema with glargine‐100 is ongoing (COMBINE 4). However, all FRCs are limited by the low GLP‐1RA dose relative to the insulin delivered. Whenever higher GLP‐1RA doses are required (i.e., in obese people), the option of separate dosing of BI and GLP‐1RA with independent titration of each component should be considered.
- Open Access
- 15 July 2025
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 35 (12) , 104233
A new role for glucagon: from secondary hormone to key player
- 15 July 2025
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 35 (12) , 104233
Open AccessA new role for glucagon: from secondary hormone to key player
- 21 March 2025
- Published by American Diabetes Association in Diabetes Care
- Vol. 48 (5) , 671-681
The Modern Role of Basal Insulin in Advancing Therapy in People With Type 2 Diabetes
Insulin deficiency, often aggravated by insulin resistance, results in type 2 diabetes mellitus (T2DM). With the availability of glucagon-like peptide 1 receptor agonists and sodium–glucose cotransporter 2 inhibitors, basal insulin (BI) therapy is no longer the first-line option after lifestyle modification plus oral agents is insufficient. In contrast to BI, the newer medications require minor titration, lower hyperglycemia in a glucose-dependent manner, and reduce body weight. Importantly, the newer agents reduce cardiorenal events in the short term. Nonetheless, insulin therapy continues to play a key role in control of hyperglycemia and therefore long-term prevention of vascular complications. Its use is essential in many circumstances, including metabolic emergencies, new diabetes onset, latent autoimmune diabetes (LADA), pregnancy, and when other agents are less desirable due to comorbidities. BI is needed in the frequent condition of failure of other therapies to keep HbA1c to target and/or intolerance of them. There are several advantages to the combination of BI with the newer medications given their different but complementary mechanisms of action, primarily, the lower dose of each, improving adherence and outcomes while decreasing the side effects. Multiple choices for single or combination use can better meet the variety of clinical phenotypes in the heterogeneous T2DM population, using the tenets of precision medicine.
- 21 March 2025
- Published by American Diabetes Association in Diabetes Care
- Vol. 48 (5) , 671-681
The Modern Role of Basal Insulin in Advancing Therapy in People With Type 2 Diabetes
Insulin deficiency, often aggravated by insulin resistance, results in type 2 diabetes mellitus (T2DM). With the availability of glucagon-like peptide 1 receptor agonists and sodium–glucose cotransporter 2 inhibitors, basal insulin (BI) therapy is no longer the first-line option after lifestyle modification plus oral agents is insufficient. In contrast to BI, the newer medications require minor titration, lower hyperglycemia in a glucose-dependent manner, and reduce body weight. Importantly, the newer agents reduce cardiorenal events in the short term. Nonetheless, insulin therapy continues to play a key role in control of hyperglycemia and therefore long-term prevention of vascular complications. Its use is essential in many circumstances, including metabolic emergencies, new diabetes onset, latent autoimmune diabetes (LADA), pregnancy, and when other agents are less desirable due to comorbidities. BI is needed in the frequent condition of failure of other therapies to keep HbA1c to target and/or intolerance of them. There are several advantages to the combination of BI with the newer medications given their different but complementary mechanisms of action, primarily, the lower dose of each, improving adherence and outcomes while decreasing the side effects. Multiple choices for single or combination use can better meet the variety of clinical phenotypes in the heterogeneous T2DM population, using the tenets of precision medicine.
- Open Access
- 15 June 2024
- Published by Springer Nature in Diabetes Therapy
- Vol. 15 (8) , 1769-1784
Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis
Introduction This study aimed to evaluate glycemic outcomes in subphenotypes of type 2 diabetes (T2D) with HbA1c > 7.0%, previously on basal insulin (pre-BI) alone (≥ 42 U/day) or on basal-bolus therapy (pre-BB), and who were switched to either basal insulin glargine 300 U/mL (IGlar-300) or 100 U/mL (IGlar-100), with or without pre-prandial insulin. Methods Participants from EDITION 2 (pre-BI, n = 785), and EDITION 1 (pre-BB, n = 792) trials were assigned retrospectively to subphenotypes of T2D: severe insulin deficient diabetes (SIDD), mild age-related diabetes (MARD), mild obesity diabetes (MOD), and severe insulin resistant diabetes (SIRD). Key efficacy and safety parameters were analyzed at baseline, and after 26 weeks, for IGlar-300 and IGlar-100 pooled groups according to subphenotypes. Outcomes were also compared with insulin-naïve subphenotypes on oral antihyperglycemic drugs (OADs) from the EDITION 3 trial (pre-OAD, n = 858). Results Pre-BI and pre-BB treated subphenotypes with SIDD had a higher mean HbA1c (8.9% and 9.1%) at baseline compared to those of MARD (7.7% and 7.8%) and MOD (8.1% and 8.2%) and after 26 weeks remained above target HbA1c (7.7% and 8.0%) despite mean glargine doses of 0.7 to 1.0 U/kg/day and pre-prandial insulin use in the pre-BB SIDD subgroup. Pre-BB treated individuals with MARD and MOD achieved lower HbA1c levels (6.9% and 7.2%) than the pre-BI groups (7.3% and 7.5%) despite similar mean FPG levels (123–130 mg/dL). Only 19–22% of participants with SIDD achieved HbA1c < 7.0% compared to 33–51% with MARD and MOD, respectively. Pre-BI and pre-BB treated subphenotypes experienced more hypoglycemia than pre-OAD treated subphenotypes. Conclusion Individuals with T2D assigned post hoc to the SIDD subphenotype achieved suboptimal glycemic control with glargine regimens including basal-bolus therapy, alerting clinicians to improve further diabetes treatment, particularly post-prandial glycemic control, in individuals with SIDD.
- 15 June 2024
- Published by Springer Nature in Diabetes Therapy
- Vol. 15 (8) , 1769-1784
Open AccessResponses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis
Introduction This study aimed to evaluate glycemic outcomes in subphenotypes of type 2 diabetes (T2D) with HbA1c > 7.0%, previously on basal insulin (pre-BI) alone (≥ 42 U/day) or on basal-bolus therapy (pre-BB), and who were switched to either basal insulin glargine 300 U/mL (IGlar-300) or 100 U/mL (IGlar-100), with or without pre-prandial insulin. Methods Participants from EDITION 2 (pre-BI, n = 785), and EDITION 1 (pre-BB, n = 792) trials were assigned retrospectively to subphenotypes of T2D: severe insulin deficient diabetes (SIDD), mild age-related diabetes (MARD), mild obesity diabetes (MOD), and severe insulin resistant diabetes (SIRD). Key efficacy and safety parameters were analyzed at baseline, and after 26 weeks, for IGlar-300 and IGlar-100 pooled groups according to subphenotypes. Outcomes were also compared with insulin-naïve subphenotypes on oral antihyperglycemic drugs (OADs) from the EDITION 3 trial (pre-OAD, n = 858). Results Pre-BI and pre-BB treated subphenotypes with SIDD had a higher mean HbA1c (8.9% and 9.1%) at baseline compared to those of MARD (7.7% and 7.8%) and MOD (8.1% and 8.2%) and after 26 weeks remained above target HbA1c (7.7% and 8.0%) despite mean glargine doses of 0.7 to 1.0 U/kg/day and pre-prandial insulin use in the pre-BB SIDD subgroup. Pre-BB treated individuals with MARD and MOD achieved lower HbA1c levels (6.9% and 7.2%) than the pre-BI groups (7.3% and 7.5%) despite similar mean FPG levels (123–130 mg/dL). Only 19–22% of participants with SIDD achieved HbA1c < 7.0% compared to 33–51% with MARD and MOD, respectively. Pre-BI and pre-BB treated subphenotypes experienced more hypoglycemia than pre-OAD treated subphenotypes. Conclusion Individuals with T2D assigned post hoc to the SIDD subphenotype achieved suboptimal glycemic control with glargine regimens including basal-bolus therapy, alerting clinicians to improve further diabetes treatment, particularly post-prandial glycemic control, in individuals with SIDD.
- Open Access
- 20 October 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (2) , 503-511
Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial
Introduction: To compare responses to basal insulin glargine 300 U/ml (IGlar‐300) and 100 U/ml (IGlar‐100) in newly defined subphenotypes of type 2 diabetes. Methods: Insulin‐naive participants (n = 858) from the EDITION 3 trial were assigned to subphenotypes ‘Mild Age‐Related Diabetes (MARD)’, ‘Mild Obesity Diabetes (MOD)’, ‘Severe Insulin Resistant Diabetes (SIRD)’ and ‘Severe Insulin Deficient Diabetes (SIDD)’. Key variables were analysed at baseline and 26 weeks. Results: Participants were comprised of MOD 56.1% (n = 481), SIDD 22.1% (n = 190), MARD 18.2% (n = 156) and SIRD 3.0% (n = 26). After 26 weeks a similar decrease in glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG) of 16‐19 mmol/mol and 1.4‐1.7 mmol/L, respectively, occurred in MARD and MOD with both insulins. SIDD had the most elevated HbA1c and FPG (80‐83 mmol/mol/11.1‐11.4 mmol/L) and reduction in both HbA1c and FPG was greater with IGlar‐100 than with IGlar‐300 (−18 vs. −15 mmol/mol and −1.6 vs. −1.3 mmol/L, respectively; each p = .03). In SIDD, despite receiving the highest basal insulin doses, HbA1c decline (57‐60 mmol/mol/7.3‐7.6%) was suboptimal at week 26. In MOD and SIDD lower incidences with IGlar‐300 were found for level 1 nocturnal hypoglycaemia [odds ratio (OR) 0.59, 95% confidence intervals (CI) 0.36‐0.97; OR 0.49, 95% CI 0.24‐0.99]. In addition, fewer level 2 hypoglycaemia episodes occurred at any time with IGlar‐300 in SIDD (OR 0.31, 95% CI 0.13‐0.77). Conclusion: Both insulins produce comparable outcomes in type 2 diabetes subphenotypes, but in SIDD, add‐on treatment to basal insulin is required to achieve glycaemic targets.
- 20 October 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (2) , 503-511
Open AccessTreatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial
Introduction: To compare responses to basal insulin glargine 300 U/ml (IGlar‐300) and 100 U/ml (IGlar‐100) in newly defined subphenotypes of type 2 diabetes. Methods: Insulin‐naive participants (n = 858) from the EDITION 3 trial were assigned to subphenotypes ‘Mild Age‐Related Diabetes (MARD)’, ‘Mild Obesity Diabetes (MOD)’, ‘Severe Insulin Resistant Diabetes (SIRD)’ and ‘Severe Insulin Deficient Diabetes (SIDD)’. Key variables were analysed at baseline and 26 weeks. Results: Participants were comprised of MOD 56.1% (n = 481), SIDD 22.1% (n = 190), MARD 18.2% (n = 156) and SIRD 3.0% (n = 26). After 26 weeks a similar decrease in glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG) of 16‐19 mmol/mol and 1.4‐1.7 mmol/L, respectively, occurred in MARD and MOD with both insulins. SIDD had the most elevated HbA1c and FPG (80‐83 mmol/mol/11.1‐11.4 mmol/L) and reduction in both HbA1c and FPG was greater with IGlar‐100 than with IGlar‐300 (−18 vs. −15 mmol/mol and −1.6 vs. −1.3 mmol/L, respectively; each p = .03). In SIDD, despite receiving the highest basal insulin doses, HbA1c decline (57‐60 mmol/mol/7.3‐7.6%) was suboptimal at week 26. In MOD and SIDD lower incidences with IGlar‐300 were found for level 1 nocturnal hypoglycaemia [odds ratio (OR) 0.59, 95% confidence intervals (CI) 0.36‐0.97; OR 0.49, 95% CI 0.24‐0.99]. In addition, fewer level 2 hypoglycaemia episodes occurred at any time with IGlar‐300 in SIDD (OR 0.31, 95% CI 0.13‐0.77). Conclusion: Both insulins produce comparable outcomes in type 2 diabetes subphenotypes, but in SIDD, add‐on treatment to basal insulin is required to achieve glycaemic targets.
- Open Access
- 13 July 2023
- Published by American Diabetes Association in Diabetes
- Vol. 72 (10) , 1364-1373
Diurnal Cycling of Insulin Sensitivity in Type 2 Diabetes: Evidence for Deviation From Physiology at an Early Stage
The aim of this study was to establish the contribution of insulin resistance to the morning (a.m.) versus afternoon (p.m.) lower glucose tolerance of people with type 2 diabetes (T2D). Eleven subjects with T2D (mean [SD] diabetes duration 0.79 [0.23] years, BMI 28.3 [1.8] kg/m2, A1C 6.6% [0.26%] [48.9 (2.9) mmol/mol]), treatment lifestyle modification only) and 11 matched control subjects without diabetes were monitored between 5:00 and 8:00 a.m. and p.m. (in random order) on one occasion (study 1), and on a subsequent occasion, they underwent an isoglycemic clamp (a.m. and p.m., both between 5:00 and 8:00, insulin infusion rate 10 mU/m2/min) (study 2). In study 1, plasma glucose, insulin, C-peptide, and glucagon were higher and insulin clearance lower in subjects with T2D a.m. versus p.m. and versus control subjects (P < 0.05), whereas free fatty acid, glycerol, and β-hydroxybutyrate were lower a.m. versus p.m. However, in study 2 at identical hyperinsulinemia a.m. and p.m. (∼150 pmol/L), glucose Ra and glycerol Ra were both less suppressed a.m. versus p.m. (P < 0.05) in subjects with T2D. In contrast, in control subjects, glucose Ra was more suppressed a.m. versus p.m. Leucine turnover was no different a.m. versus p.m. In conclusion, in subjects with T2D, insulin sensitivity for glucose (liver) and lipid metabolism has diurnal cycles (nadir a.m.) opposite that of control subjects without diabetes already at an early stage, suggesting a marker of T2D. Article Highlights: In people with type 2 diabetes (T2D), fasting hyperglycemia is greater in the morning (a.m.) versus the afternoon (p.m.), and insulin sensitivity for glucose and lipid metabolism is lower a.m. versus p.m. This pattern is the reverse of the physiological diurnal cycle of people without diabetes who are more insulin sensitive a.m. versus p.m. These new findings have been observed in the present study in people without obesity but with recent-onset T2D, with good glycemic control, and in the absence of confounding pharmacological treatment. It is likely that the findings represent a specific marker of T2D, possibly present even in prediabetes before biochemical and clinical manifestations.
- 13 July 2023
- Published by American Diabetes Association in Diabetes
- Vol. 72 (10) , 1364-1373
Open AccessDiurnal Cycling of Insulin Sensitivity in Type 2 Diabetes: Evidence for Deviation From Physiology at an Early Stage
The aim of this study was to establish the contribution of insulin resistance to the morning (a.m.) versus afternoon (p.m.) lower glucose tolerance of people with type 2 diabetes (T2D). Eleven subjects with T2D (mean [SD] diabetes duration 0.79 [0.23] years, BMI 28.3 [1.8] kg/m2, A1C 6.6% [0.26%] [48.9 (2.9) mmol/mol]), treatment lifestyle modification only) and 11 matched control subjects without diabetes were monitored between 5:00 and 8:00 a.m. and p.m. (in random order) on one occasion (study 1), and on a subsequent occasion, they underwent an isoglycemic clamp (a.m. and p.m., both between 5:00 and 8:00, insulin infusion rate 10 mU/m2/min) (study 2). In study 1, plasma glucose, insulin, C-peptide, and glucagon were higher and insulin clearance lower in subjects with T2D a.m. versus p.m. and versus control subjects (P < 0.05), whereas free fatty acid, glycerol, and β-hydroxybutyrate were lower a.m. versus p.m. However, in study 2 at identical hyperinsulinemia a.m. and p.m. (∼150 pmol/L), glucose Ra and glycerol Ra were both less suppressed a.m. versus p.m. (P < 0.05) in subjects with T2D. In contrast, in control subjects, glucose Ra was more suppressed a.m. versus p.m. Leucine turnover was no different a.m. versus p.m. In conclusion, in subjects with T2D, insulin sensitivity for glucose (liver) and lipid metabolism has diurnal cycles (nadir a.m.) opposite that of control subjects without diabetes already at an early stage, suggesting a marker of T2D. Article Highlights: In people with type 2 diabetes (T2D), fasting hyperglycemia is greater in the morning (a.m.) versus the afternoon (p.m.), and insulin sensitivity for glucose and lipid metabolism is lower a.m. versus p.m. This pattern is the reverse of the physiological diurnal cycle of people without diabetes who are more insulin sensitive a.m. versus p.m. These new findings have been observed in the present study in people without obesity but with recent-onset T2D, with good glycemic control, and in the absence of confounding pharmacological treatment. It is likely that the findings represent a specific marker of T2D, possibly present even in prediabetes before biochemical and clinical manifestations.
- 5 September 2022
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 24 (12) , 2474-2477
A comparison of the effectiveness and safety of insulin glargine 300 U/ ml versus 100 U/ ml in children and adolescents with newly diagnosed type 1 diabetes: A retrospective, observational, short‐term study
- 5 September 2022
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 24 (12) , 2474-2477
A comparison of the effectiveness and safety of insulin glargine 300 U/ ml versus 100 U/ ml in children and adolescents with newly diagnosed type 1 diabetes: A retrospective, observational, short‐term study